Breast cancer is good for about a third of all new female cancers in the US every year
An experimental treatment by Pfizer and Arvinas delayed the progression of breast cancer with more than three months compared to AstraZeneca’s Faslodex in patients with a specific gene mutation, according to the results of the test announced on Saturday.
The findings were presented in Chicago during the annual meeting of the American Society of Clinical Oncology and published in the New England Journal of Medicine.
The study showed that the experimental drug Vepdegestrant increased the survival without the progression of the disease in patients with ESR1 mutations by five months compared to about two months for Faslodex.
The findings followed the first results of the investigation in March. They showed the benefit of Vep degeste strant in patients with the mutations, but could not show an advantage in a larger set of patients, which sent Arvinas’s shares to a record low.
The more detailed data from Saturday showed that Vepdegestrant increased the survival in the larger group of patients by 3.8 months, versus 3.6 months for Faslodex.
The late stage examination has previously treated 624 with a kind of breast cancer that accounts for almost 70 percent of all such cancers.
Erica Hamilton, one of the authors of the study, said that Faslodex “now clearly has some challenges”, adding that it is injected into a muscle, versus the easier oral dosage of Vepdegestrant.
Vepdegestrant belongs to a new class of drugs called Protac er -breakers, which are designed to use the natural protein removal system of the body to focus specifically and break down proteins that stimulate tumor growth.
According to the American Cancer Society, breast cancer is about a third of all new female cancers in the US.
Approved treatments for this type of advanced breast cancer are Eli Lilly’s Versezenio, Pfizer’s Ibrance and Novartis’ Kisqali.
Leerink Partners analyst Andrew Berens expects VepdeGestrant to earn $ 576 million in peak sales in 2032.
Earlier this month Arvinas said that it will not continue with two other planned late stage studies of the medicine.
More so
Published on May 31, 2025
#Breast #cancer #PfizerArvinas #drug #beats #AstraZeneca #slowing #progression #disease